CONSENSUS
As of January 07, 2026
| Q4 2025 | FY 2025 | FY 2026 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute values, in M USD | Constant currency YoY growth | Reported YoY growth | Absolute values, in M USD | Constant currency YoY growth | Reported YoY growth | Absolute values, in M USD | Constant currency YoY growth | Reported YoY growth | |||
| Net sales | 1,459 | 23.7% | 26.7% | 5,197 | 17.3% | 17.8% | 6,167 | 17.5% | 18.7% | ||
| Injectable Aesthetics | 683 | 11.2% | 14.0% | 2,556 | 10.8% | 11.2% | 2,901 | 12.2% | 13.4% | ||
| Neuromodulators | 407 | 10.6% | 13.4% | 1,460 | 13.2% | 13.6% | 1,676 | 13.6% | 14.8% | ||
| Fillers & Biostimulators | 278 | 12.1% | 14.9% | 1,097 | 7.7% | 8.1% | 1,224 | 10.5% | 11.6% | ||
| Dermatological Skincare | 396 | 12.9% | 16.2% | 1,459 | 9.1% | 9.6% | 1,603 | 8.6% | 9.8% | ||
| Therapeutic Dermatology | 377 | 78.6% | 80.7% | 1,181 | 50.9% | 51.4% | 1,664 | 39.4% | 40.9% | ||
| Nemluvio | 186 | 449 | 948 | ||||||||
| Core EBITDA1 | 1,208 | 1,596 | |||||||||
| Core net income2 | 729 | 1,074 | |||||||||
The consensus has been collated from estimates submitted to Galderma, ahead of quarterly reporting. It covers 12 estimates, with participating analysts from: Barclays, Berenberg, BofA Securities, BNP Paribas Exane, Goldman Sachs, Jefferies, J.P. Morgan, Kepler Cheuvreux, Morgan Stanley, RBC, UBS, and Vontobel. The information is provided solely for convenience to users of our website, for information purposes only.
The consensus is a collection of analysts' own projections, which are neither checked, updated, nor endorsed by Galderma. Galderma will not provide any commentary on the consensus or answer questions on it. Consensus estimates are forward-looking and are based on assumptions about future developments, some or all of which may not occur. The methodology or circulation of the consensus is not mandatory; therefore, Galderma assumes no liability in connection with the compilation and publication of consensus estimates. Galderma may amend its practice at any time.
1. Core EBITDA: defined as EBITDA excluding the following items that are deemed exceptional, including acquisition and disposal, integration and carve-out related income and expenses, onerous contracts, business disposal gains and losses, restructuring and reorganisation related items, litigation related items, impairment of Property, plant and equipment, and software, IPO related incentive plans as well as other income and expense items that management deems exceptional and that are expected to accumulate within the year to be over 1 M USD threshold. These include transformation, carve-out and build-up related project costs as well as post-acquisition related accounting impacts
2. Core net income: defined as net income / (loss) from continuing operations excluding the same items that are deemed exceptional for the purpose of the Core EBITDA definition, as well as amortization of intangible assets, foreign exchange gains and losses on financing activities. Taxes on the adjustments between IFRS and Core Net Income take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact